The Innovative Medicines Initiative (IMI) opened 2 new calls.

A new Antimicrobial Resistance (AMR) Accelerator Programme is part of new Calls for proposals launched today by the Innovative Medicines Initiative (IMI).

Of the other topics launched in the Calls, many address brain disorders (e.g. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major depression) and immune-mediated diseases (e.g. rheumatoid arthritis and lupus as well as inflammatory bowel diseases such as Crohn’s and colitis, and skin diseases like dermatitis and psoriasis). Among other things, the topics aim to make clinical trials more patient-centric, contribute to medicines safety, and apply blockchain technologies to the drug development and health sectors.

Deadline for proposals: 24 October 2018

More information

Tags: No tags

Comments are closed.